BioSpace News Archive

Mark Veich, president of Advancium Health Network and executive director of the Deerfield Foundation, characterized Cure Innovation Labs as an ‘excel-erator.’

Detailed positive results from the Phase 3 PRIME2 trial evaluating the safety and efficacy of Dupixent® was presented in a late-breaking session at the American Academy of Dermatology 2022 Annual Meeting.

Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announced new positive clinical data from EASE, the largest Phase 3 trial in Epidermolysis Bullosa.

Adults with severe alopecia areata who took OLUMIANT® achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% of those who responded to OLUMIANT 4-mg achieved 90% scalp coverage at 52 weeks, Eli Lilly and Company and Incyte announced at the American Academy of Dermatology Annual Meeting.

Evelo Biosciences, Inc. presented a late-breaking oral abstract on data from a Phase 2 trial of EDP1815 in psoriasis at the 2022 American Academy of Dermatology Annual Meeting, being held March 25-29 in Boston, Massachusetts.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that detailed positive results from the Phase 3 PRIME2 trial evaluating the efficacy and safety of Dupixent® were presented in a late-breaking session at the American Academy of Dermatology 2022 Annual Meeting.

Incyte announced new 52-week results from its pivotal Phase 3 TRuE-V clinical trial program evaluating ruxolitinib cream, a topical JAK1/JAK2 inhibitor, in adolescent and adult patients with nonsegmental vitiligo.

Krystal Biotech, Inc., the leader in redosable gene therapies for rare diseases, presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec, an investigational, topical gene therapy, for the treatment of dystrophic epidermolysis bullosa, at the 2022 American Academy of Dermatology Annual Meeting in Boston, Mass.

Vertex Pharmaceuticals Incorporated announced that as of 1 April 2022, TRIKAFTA® will be reimbursed on the Australian Pharmaceutical Benefits Scheme for the treatment of cystic fibrosis in people ages 12 years and older who have at least one F508del mutation in the CFTR gene, the most common CF-causing mutation worldwide.

UCB, a global biopharmaceutical company, announced that it is presenting 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology Annual Meeting in Boston, Massachusetts, U.S., on March 25-29, including a late breaking oral platform presentation and 10 posters.